
News|Articles|December 5, 2025
Executive Summary: Mastering Nitrosamines Analysis With Streamlined LC-MS/MS Solutions
Author(s)SCIEX
Nitrosamine contamination in pharmaceuticals has become a major regulatory concern due to their potent carcinogenicity, requiring ultra-trace-level detection to ensure patient safety. Advanced LC-MS/MS workflows provide the necessary sensitivity, selectivity, and robustness to accurately quantify nitrosamine drug substance-related impurities (NDSRIs), even within complex pharmaceutical matrices. Case studies with betahistine, orphenadrine, and chloropyramine demonstrate how streamlined LC-MS/MS strategies can reliably detect and confirm nitrosamine impurities well below regulatory thresholds.
Trending on Pharmaceutical Technology
1
Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance
2
Renewing Prosaic Generics for Cancer Treatment
3
Faster Doesn’t Mean Easier: Development Impacts of a New Biosimilar Regulatory Landscape
4
Leveraging an Innovative Mid-Scale Manufacturing Solution to Meet Diverse Needs
5